selumetinib,azacitidine
astrazeneca
['azacitidine,(-oral azaci),(-azacitidine oral)', 'myeloid', 'selumetinib', 'mds']
congress | #asco23 | presented a phase i study of selumetinib plus azacitidine in pts with high-risk chronic myeloid neoplasms. eligibility: pts with higher risk mds, mds/mpns, and myelofibrosis. planned enrolment ~18 participants #mdssm #medicalcongress 
Lifting levels of knowledge in myelodysplastic syndromes (#MDS). A global online platform providing latest treatment options and medical information. #mdssm